These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 9824674)

  • 21. Volume transmission of dopamine over large distances may contribute to recovery from experimental parkinsonism.
    Schneider JS; Rothblat DS; DiStefano L
    Brain Res; 1994 Apr; 643(1-2):86-91. PubMed ID: 8032935
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Response of the damaged dopamine system to GM1 and semisynthetic gangliosides: effects of dose and extent of lesion.
    Schneider JS; Distefano L
    Neuropharmacology; 1995 May; 34(5):489-93. PubMed ID: 7566482
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mitochondrial toxins in models of neurodegenerative diseases. II: Elevated zif268 transcription and independent temporal regulation of striatal D1 and D2 receptor mRNAs and D1 and D2 receptor-binding sites in C57BL/6 mice during MPTP treatment.
    Smith TS; Trimmer PA; Khan SM; Tinklepaugh DL; Bennett JP
    Brain Res; 1997 Aug; 765(2):189-97. PubMed ID: 9313891
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment with GM1 ganglioside reverses dopamine D-2 receptor supersensitivity induced by the neurotoxin MPTP.
    Hadjiconstantinou M; Weihmuller F; Neff NH
    Eur J Pharmacol; 1989 Sep; 168(2):261-4. PubMed ID: 2532603
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Regional differences in striatal dopamine uptake and release associated with recovery from MPTP-induced parkinsonism: an in vivo electrochemical study.
    Rothblat DS; Schneider JS
    J Neurochem; 1999 Feb; 72(2):724-33. PubMed ID: 9930746
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Recovery of nigrostriatal and mesolimbic dopaminergic system following administration of ganglioside in MPTP-treated mice].
    Date I; Asari S; Nishimoto A; Felten DL
    No To Shinkei; 1990 Nov; 42(11):1035-40. PubMed ID: 2076347
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neurochemical evaluation of the striatum in symptomatic and recovered MPTP-treated cats.
    Schneider JS; Rothblat DS
    Neuroscience; 1991; 44(2):421-9. PubMed ID: 1944893
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Continued administration of GM1 ganglioside is required to maintain recovery from neuroleptic-induced sensorimotor deficits in MPTP-treated mice.
    Weihmuller FB; Hadjiconstantinou M; Bruno JP; Neff NH
    Life Sci; 1989; 45(25):2495-502. PubMed ID: 2532697
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Striatal enkephalin gene expression does not reflect parkinsonian signs.
    Schroeder JA; Schneider JS
    Neuroreport; 2000 Jun; 11(9):1799-802. PubMed ID: 10884022
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preproenkephalin mRNA and methionine-enkephalin increase in mouse striatum after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment.
    Gudehithlu KP; Duchemin AM; Tejwani GA; Neff NH; Hadjiconstantinou M
    J Neurochem; 1991 Mar; 56(3):1043-8. PubMed ID: 1899692
    [TBL] [Abstract][Full Text] [Related]  

  • 31. GM1 ganglioside treatment partially reverses the nigrostriatal dopamine defect in the weaver mutant mouse.
    Schneider JS; Smith MG; DiStefano L; Berrian J
    Brain Res; 1994 Feb; 636(2):353-6. PubMed ID: 7912161
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differential recovery of dopamine synthetic enzymes following MPTP and the consequences of GM1 ganglioside treatment.
    Hadjiconstantinou M; Neff NH
    Eur J Pharmacol; 1990 May; 181(1-2):137-9. PubMed ID: 1974854
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tyrosine hydroxylase and dopamine transporter expression in residual dopaminergic neurons: potential contributors to spontaneous recovery from experimental Parkinsonism.
    Rothblat DS; Schroeder JA; Schneider JS
    J Neurosci Res; 2001 Aug; 65(3):254-66. PubMed ID: 11494360
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential vulnerability of dopamine receptors in the mouse brain treated with MPTP.
    Tanji H; Araki T; Nagasawa H; Itoyama Y
    Brain Res; 1999 Apr; 824(2):224-31. PubMed ID: 10196452
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quantitative analysis of dopaminergic loss in relation to functional territories in MPTP-treated monkeys.
    Jan C; Pessiglione M; Tremblay L; Tandé D; Hirsch EC; François C
    Eur J Neurosci; 2003 Oct; 18(7):2082-6. PubMed ID: 14622241
    [TBL] [Abstract][Full Text] [Related]  

  • 36. l-dopa-induced reversal in striatal glutamate following partial depletion of nigrostriatal dopamine with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Holmer HK; Keyghobadi M; Moore C; Meshul CK
    Neuroscience; 2005; 136(1):333-41. PubMed ID: 16198485
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Response of caudate neurons to stimulation of intrinsic and peripheral afferents in normal, symptomatic, and recovered MPTP-treated cats.
    Rothblat DS; Schneider JS
    J Neurosci; 1993 Oct; 13(10):4372-8. PubMed ID: 8410193
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oral administration of semisynthetic sphingolipids promotes recovery of striatal dopamine concentrations in a murine model of parkinsonism.
    Schneider JS; DiStefano L
    Neurology; 1994 Apr; 44(4):748-50. PubMed ID: 8164837
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alterations in intralaminar and motor thalamic physiology following nigrostriatal dopamine depletion.
    Schneider JS; Rothblat DS
    Brain Res; 1996 Dec; 742(1-2):25-33. PubMed ID: 9117401
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Deficits in reaction times and movement times as correlates of hypokinesia in monkeys with MPTP-induced striatal dopamine depletion.
    Schultz W; Studer A; Romo R; Sundström E; Jonsson G; Scarnati E
    J Neurophysiol; 1989 Mar; 61(3):651-68. PubMed ID: 2785168
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.